Abstract YO13
Case summary
Background: Immunoglobulin G4 (IgG4)-related disease is a rare immune-mediated fibroinflammatory condition, characterized by infiltration of IgG4 positive plasma cells and storiform fibrosis. The clinical presentation included fibrosis of affected organs and pseudotumor formation occasionally mimic malignancy.
Aims: To present a case of IgG4-related kidney disease mimicking renal cell carcinoma
Method: Case report
Result: 53-year-old male with an unremarkable previous medical history presented with painless gross hematuria, fever and anemic symptom for 3 months. Laboratory tests showed microcytic anemia, normal creatinine levels and numerous white blood cells in urine. CT chest and abdomen revealed an infiltrative heterogenous hypoenhancing lesion at right kidney size 7.5 x7.9 x8.5cm, a hypoenhancing lesion in hepatic segment IVa/VIII size 6.8x3.8 cm, diffuse intraabdominal lymph node enlargement up to 1.8 cm and multiple lung nodules. The initial clinical and radiologic findings were highly suggestive of malignancy. The differential diagnosis is renal cell carcinoma and lymphoma. Liver biopsy was performed and shown chronic inflammation and fibrosis. Subsequently renal biopsy was done and revealed chronic interstitial nephritis, focal interstitial fibrosis and prominent plasma cell infiltration. Immunohistochemistry from renal biopsy revealed positive for CD20, CD3, CD38, CD138, IgG (210 cells/HPF) and IgG4/IgG-positive cell ratio was 54%. In situ hybridization for kappa and lambda light chain showed polyclonal plasma cell with kappa to lambda ratio of 4:1. Serum IgG4 level was more than 5,840 mg/dL. These findings made diagnosis of IgG4 related kidney disease. Prednisolone 60 mg/day was given and gradually reduced to 10 mg five months thereafter. After 3 months of therapy, a follow-up CT scan showed decrease size of right renal mass to 6.1 x7.3 x6.2 cm, nearly complete resolved of liver lesion and some prior pulmonary nodules.
Conclusion: IgG4 related kidney disease can present with pseudotumor and can be misdiagnosed as a malignant tumor. Awareness of this condition and proper investigation including histopathology and serum IgG4 level should be considered in case of highly suggestive patient.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract